Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn

Postprandial Heartburn Clinical Trial

Official title: Randomized, Controlled, Single-blind, Three-way Crossover Clinical Investigation to Evaluate Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn

Status Completed

Clinical Trial Summary

This study is a randomized, placebo-controlled, single-blind, three-way crossover clinical trial to evaluate safety and efficacy of IQP-LH-101 (tablet form and liquid form) in postprandial heartburn.

The null hypothesis is that there is no difference between IQP-LH-101 and the placebo in terms of efficacy for postprandial heartburn treatment.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Heartburn
• Postprandial Heartburn

• NCT number: NCT01718639
• Study type: Interventional
• Source: InQpharm Group
• Status: Completed
• Phase: Phase 4
• Start date: October 2012
• Completion date: March 2013